Facebook
Britain's News Portal
Around The Clock
BREAKING
Loading latest headlines…

Isomorphic Labs Secures $5bn in Major UK Tech Funding Round

AI drug discovery firm Isomorphic Labs has raised $5bn (£3.8bn) in a Series C funding round, one of the largest in British tech history.

  • Isomorphic Labs, a Google Deepmind spinout, raised $5bn (£3.8bn) in an oversubscribed Series C funding round.
  • The funding was co-led by Greenoaks and Sequoia Capital, with participation from Alphabet, Andreessen Horowitz, and the UK government’s Sovereign AI Fund.
  • The company uses AI to design potential medicines and is developing treatments for cancer and immune disorders, but has not yet begun human clinical trials.

London-based AI drug discovery firm Isomorphic Labs has secured $5bn (£3.8bn) in a Series C funding round, marking one of the largest investments in British technology. The Google Deepmind spinout, led by Nobel Prize-winning scientist Sir Demis Hassabis, announced the oversubscribed round on Tuesday, 17 November 2026.

The funding was co-led by US venture capital firms Greenoaks and Sequoia Capital. Other participants included Andreessen Horowitz, Alphabet, Thrive Capital, MGX, GV, Capital G, Temasek, and the UK government’s Sovereign AI Fund. This investment follows a $2.1bn Series B funding round six months prior, bringing total disclosed external funding to approximately $7.7bn since 2025.

Isomorphic Labs, founded in 2021, uses its proprietary drug design engine, 'IsoDDE', to predict how molecules interact with biological targets. This aims to reduce the time and cost associated with drug development. The company is developing its own medicines for cancer and immune disorders, and also has partnerships with pharmaceutical companies such as Eli Lilly, Novartis, and Johnson & Johnson.

Despite raising billions, Isomorphic Labs has not yet commenced human testing of its drug candidates. The company is reportedly in late-stage preclinical development, with early results described as encouraging across its internal oncology and immunology programmes and partnered projects. The new funding is intended to support the development of its AI models, expand its drug pipeline, and build global bioengineering infrastructure as it prepares for clinical trials.

AI minister Kanishka Narayan welcomed the announcement, stating that Isomorphic Labs' work “could fundamentally change how new medicines are discovered and accelerate the development of life-changing treatments for patients around the world.” Sir Demis Hassabis added that the funding will enable the company to accelerate progress in building foundational biology models, deepening systemic disease understanding, and driving therapeutic programs towards clinical trials.

Why this matters: This significant investment highlights growing investor confidence in AI's potential to transform the pharmaceutical industry and accelerate the discovery of new medicines.

Related Articles

Get the news that matters.

Join thousands of readers getting the best of British news straight to their inbox.